Publications
Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
Author comment on Dual blockade of the PI3K/AKT/mTOR(AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergystically inhibits rhabdomyosarcoma...
A collaborative effort to compare the molecular changes across the original 12 tumor types profiled by The Cancer Genome Atlas.
A review on the role of MYCN and other newly identifed drivers in neuroblastoma.
Using a newly developed platform to identify the signaling pathway/molecular target of natural products, we identified a family of alkaloid natural products, discoipyrroles A-D (1-4), from Bacillus hunanensis that inhibit the DDR2 signaling pathway.
3q26 is frequently amplified in several cancer types with a common amplified region containing 20 genes. To identify cancer driver genes in this region, we interrogated the function of each of these genes.
The Cancer Therapeutics Response Portal (www.broadinstitute.org/ctrp) was created to identify cancer genotype-compound sensitivity relationships.
Researchers introduce the PiHelper, which integrates human drug-target and antibody-target associations from publicly available resources to help meet the needs of researchers in systems pharmacology, perturbation biology and proteomics.
By utilizing whole-genome sequencing, DNA copy number analysis and RNA-seq, researchers discovered recurrent somatic point mutations and genes that were targeted by focal somatic deletions in diffuse large B-cell lymphoma (DLBCL).
Using nanofluidic proteomic immunoassay researchers demonstrate that under basal and ligand-induced conditions that the pattern of phosphorylation events is markedly different between AKT1 and AKT2.
Pages
